AB Core Bond ETF (EYEG)
- Previous Close
34.65 - Open
34.72 - Bid 34.58 x 100
- Ask 34.77 x 100
- Day's Range
34.71 - 34.77 - 52 Week Range
34.52 - 36.24 - Volume
5,800 - Avg. Volume
307 - Net Assets 24.96M
- NAV 34.56
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return -2.50%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.30%
The fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers may include corporate or other business entities in which a sovereign or governmental agency or entity may have, indirectly or directly, an interest, including a majority or greater ownership interest.
AllianceBernstein
Fund Family
Corporate Bond
Fund Category
24.96M
Net Assets
2023-12-12
Inception Date
Performance Overview: EYEG
Trailing returns as of 4/18/2024. Category is Corporate Bond.
People Also Watch
Related ETF News
Research Reports: EYEG
NEO: What does Argus have to say about NEO?
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $52.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetNEO: Raising target price to $52.00
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $52.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetNEO: Lowering target price to $50.00
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $50.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetVNDA: What does Argus have to say about VNDA?
VANDA PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice Target